Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
Epicrispr Biotechnologies has raised $68.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Epicrispr Biotechnologies's investors include Ally Bridge Group, Solve FSHD.
Epicrispr Biotechnologies is headquartered in South San Francisco, United States.
Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.
Epicrispr Biotechnologies is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Epicrispr Biotechnologies — Funding & Investors." VCBacked, March 26, 2025, https://www.vcbacked.co/company/epicrispr-biotechnologies. Accessed August 1, 2026.
VCBacked. (2025). Epicrispr Biotechnologies — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/epicrispr-biotechnologies
{{cite web |title=Epicrispr Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/epicrispr-biotechnologies |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated